Zecotek Photonics Inc. (TSX
VENTURE:ZMS)(FRANKFURT:W1I), a developer of leading-edge photonics technologies
for medical, industrial and scientific markets, today announced that the National
Cancer Institute, a division of the U.S. National Institutes of Health (NIH),
has selected its proprietary Tunable Green Fiber Laser (TGFL) for research in
flow cytometry. The TGFL is the world's first tunable fiber laser emitting in
the visible wavelength range. This latest order follows the purchase by the
National Cancer Institute of Zecotek's Fixed Wavelength Green Fiber Laser (FGFL),
for cytometric research. Dr. William Telford, Head of the Flow Cytometry Core
Laboratory at the National Cancer Institute/NIH is leading the experimental
work to be conducted with this laser.
"The wavelength range that Zecotek's Tunable Green Fiber Laser provides
is ideal for our research which is aimed at discovering new fluorescent probes
for application in immunology, hematology, organ transplantation and biomedical
research," said Dr. Telford.
"We are very gratified the National Cancer Institute has selected our
Tunable Green Fiber Laser for an area of research that directly contributes
to advancements in bio-instrumentation," said Dr. A.F. Zerrouk, Chairman,
President, and CEO of Zecotek. "Dr. Telford's research is closely followed
by industry and his results have contributed to the strong interest from bio-instrumentation
OEMs in our FGFL and TGFL for flow cytometry and other systems which, we anticipate,
will contribute to strong sales growth in early 2010."
Under an extension of the joint manufacturing agreement with Fujikura, the
FGFL and TGFL series will carry the Zecotek label in North America, with manufacturing
and manufacturer's warranty remaining with Fujikura of Japan.